Keep me updated about investment opportunities in the area of oncology and life sciences.
TRACON Pharmaceuticals doses first patient in Phase I/II study of TRC253 in patients with prostate cancer
Jounce Therapeutics to present Phase 1 data from JTX-2011 ICONIC trial at 2017 american society of clinical oncology
Blueprint Medicines to present new data from ongoing Phase 1 clinical trial of BLU-285 in Patients with advanced GIST at 2017 ASCO annual meeting
Peloton Therapeutics initiates patient dosing in Phase 2 study of PT2385 for von Hippel-Lindau disease-associated kidney cancer
TRACON Pharmaceuticals announces publication in Blood of preclinical data indicating activity of TRC105 in acute myeloid leukemia and B-cell acute lymphoblastic leukemia
TRACON Pharmaceuticals reports first quarter financial results and provides corporate update
Sunesis Pharmaceuticals reports first quarter 2017 financial results and recent highlights
Sunesis Pharmaceuticals announces withdrawal of European Marketing Authorization Application (MAA) for vosaroxin as a treatment for relapsed/refractory AML
Blueprint Medicines to report first quarter 2017 financial results on Wednesday, May 3, 2017
Jounce Therapeutics initiates Phase 2 portion of ICONIC study of JTX-2011 in patients with advanced solid tumors.
Tracon awarded 'Most Innovative Trial Design' for Phase 3 TAPPAS clinical trial of TRC105 in angiosarcoma at 2017 Clinical and Research Excellence Awards
Your eMail have been successfully registered.Close